Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography

O. Clyde Hutchinson; David R. Collingridge; Henryk Barthel; Pat M. Price; Eric O. Aboagye

doi:10.2174/1381612033455288

Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography

O. Clyde Hutchinson, David R. Collingridge, Henryk Barthel, Pat M. Price, Eric O. Aboagye

Research output: Contribution to journal › Article › peer-review

Abstract

Positron emission tomography (PET) provides the oncologist with information on tumour diagnosis, and treatment response monitoring. Mathematical modelling of tissue data, and online plasma radioactive metabolite profiling, enables important tissue kinetic parameters relating to the uptake, distribution and washout as well as arterial input function to be derived. The resultant kinetic data allow for not only diagnosis but also the assessment of therapeutic response endpoints. These endpoints can be used to measure specific therapeutic effects. This novel application of PET can provide information that is often difficult to measure in the intact animal or patient. The pharmacokinetics of radiolabelled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA), temozolomide and 5-fluorouracil (5-FU) are described.

Original language	English
Pages (from-to)	917-929
Number of pages	12
Journal	Current Pharmaceutical Design
Volume	9
Issue number	11
DOIs	https://doi.org/10.2174/1381612033455288
Publication status	Published - 2003

Keywords

pharmacokinetics: Acridines
Animals
chemistry: Antineoplastic Agents
analogs & derivatives: Dacarbazine
chemistry: Fluorouracil
Humans
Molecular Structure
Radioactive Tracers
chemistry: Radiopharmaceuticals
Tissue Distribution
Tomography, Emission-Computed

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2174/1381612033455288

Cite this

@article{96b25358366d43d88eebe057460921a0,

title = "Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography",

abstract = "Positron emission tomography (PET) provides the oncologist with information on tumour diagnosis, and treatment response monitoring. Mathematical modelling of tissue data, and online plasma radioactive metabolite profiling, enables important tissue kinetic parameters relating to the uptake, distribution and washout as well as arterial input function to be derived. The resultant kinetic data allow for not only diagnosis but also the assessment of therapeutic response endpoints. These endpoints can be used to measure specific therapeutic effects. This novel application of PET can provide information that is often difficult to measure in the intact animal or patient. The pharmacokinetics of radiolabelled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA), temozolomide and 5-fluorouracil (5-FU) are described.",

keywords = "pharmacokinetics: Acridines, Animals, chemistry: Antineoplastic Agents, analogs & derivatives: Dacarbazine, chemistry: Fluorouracil, Humans, Molecular Structure, Radioactive Tracers, chemistry: Radiopharmaceuticals, Tissue Distribution, Tomography, Emission-Computed",

author = "Hutchinson, {O. Clyde} and Collingridge, {David R.} and Henryk Barthel and Price, {Pat M.} and Aboagye, {Eric O.}",

year = "2003",

doi = "10.2174/1381612033455288",

language = "English",

volume = "9",

pages = "917--929",

journal = "Current Pharmaceutical Design",

issn = "1381-6128",

publisher = "Bentham Science Publishers",

number = "11",

}

TY - JOUR

T1 - Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography

AU - Hutchinson, O. Clyde

AU - Collingridge, David R.

AU - Barthel, Henryk

AU - Price, Pat M.

AU - Aboagye, Eric O.

PY - 2003

Y1 - 2003

N2 - Positron emission tomography (PET) provides the oncologist with information on tumour diagnosis, and treatment response monitoring. Mathematical modelling of tissue data, and online plasma radioactive metabolite profiling, enables important tissue kinetic parameters relating to the uptake, distribution and washout as well as arterial input function to be derived. The resultant kinetic data allow for not only diagnosis but also the assessment of therapeutic response endpoints. These endpoints can be used to measure specific therapeutic effects. This novel application of PET can provide information that is often difficult to measure in the intact animal or patient. The pharmacokinetics of radiolabelled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA), temozolomide and 5-fluorouracil (5-FU) are described.

AB - Positron emission tomography (PET) provides the oncologist with information on tumour diagnosis, and treatment response monitoring. Mathematical modelling of tissue data, and online plasma radioactive metabolite profiling, enables important tissue kinetic parameters relating to the uptake, distribution and washout as well as arterial input function to be derived. The resultant kinetic data allow for not only diagnosis but also the assessment of therapeutic response endpoints. These endpoints can be used to measure specific therapeutic effects. This novel application of PET can provide information that is often difficult to measure in the intact animal or patient. The pharmacokinetics of radiolabelled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA), temozolomide and 5-fluorouracil (5-FU) are described.

KW - pharmacokinetics: Acridines

KW - Animals

KW - chemistry: Antineoplastic Agents

KW - analogs & derivatives: Dacarbazine

KW - chemistry: Fluorouracil

KW - Humans

KW - Molecular Structure

KW - Radioactive Tracers

KW - chemistry: Radiopharmaceuticals

KW - Tissue Distribution

KW - Tomography, Emission-Computed

U2 - 10.2174/1381612033455288

DO - 10.2174/1381612033455288

M3 - Article

SN - 1381-6128

VL - 9

SP - 917

EP - 929

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

IS - 11

ER -

Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this